To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 (A) Progression-free survival (PFS) and (B) overall survival (OS) for 464 patients treated with HD IL-2/IFN as first-line treatment for metastatic melanoma with a median follow-up time of 6.4 years. HD, high-dose; IFN; interferon; IL-2, interleukin-2. Fig.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile